Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone Presented at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Atlanta, GA, October 3–7, 2004.
dc.contributor.author | Horwitz, Eric M. | en_US |
dc.contributor.author | Levy, Lawrence B. | en_US |
dc.contributor.author | Thames, Howard D. | en_US |
dc.contributor.author | Kupelian, Patrick A. | en_US |
dc.contributor.author | Martinez, Alvaro A. | en_US |
dc.contributor.author | Michalski, Jeffrey M. | en_US |
dc.contributor.author | Pisansky, Thomas M. | en_US |
dc.contributor.author | Sandler, Howard M. | en_US |
dc.contributor.author | Shipley, William U. | en_US |
dc.contributor.author | Zelefsky, Michael J. | en_US |
dc.contributor.author | Zietman, Anthony L. | en_US |
dc.contributor.author | Kuban, Deborah A. | en_US |
dc.date.accessioned | 2007-09-20T17:41:00Z | |
dc.date.available | 2008-01-03T16:19:17Z | en_US |
dc.date.issued | 2006-10-01 | en_US |
dc.identifier.citation | Horwitz, Eric M.; Levy, Lawrence B.; Thames, Howard D.; Kupelian, Patrick A.; Martinez, Alvaro A.; Michalski, Jeffrey M.; Pisansky, Thomas M.; Sandler, Howard M.; Shipley, William U.; Zelefsky, Michael J.; Zietman, Anthony L.; Kuban, Deborah A. (2006). "Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone Presented at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Atlanta, GA, October 3–7, 2004. ." Cancer 107(7): 1496-1502. <http://hdl.handle.net/2027.42/55827> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/55827 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16944536&dopt=citation | en_US |
dc.description.abstract | BACKGROUND. The posttreatment prostate-specific antigen (PSA) bounce phenomenon has been recognized in at least 20% of all patients treated with radiation. The purpose of the current report was to determine if there was a difference in biochemical and clinical control between the bounce and nonbounce (NB) patients using pooled data on 4839 patients with T1-2 prostate cancer treated with external beam radiation therapy (RT) alone at 9 institutions between 1986 and 1995. METHODS. The median follow-up was 6.3 years. A posttreatment PSA bounce was defined by a minimal rise of 0.4 ng/mL over a 6-month follow-up period, followed by a drop in PSA level of any magnitude. Endpoints included no biochemical evidence of disease (bNED) failure (BF) (ASTRO definition), distant failure (DF), cause-specific failure (CSF), and overall survival (OS). Patients were stratified by pretreatment PSA, Gleason score, T stage, age, dose, and risk group. RESULTS. In all, 978 (20%) patients experienced at least 1 posttreatment PSA bounce. Within 3 subgroups (risk group, pretreatment PSA, and age), statistically significant differences of remaining bounce-free were observed on univariate analysis. Patients < 70 years had a 72% chance of remaining bounce-free at 5 years compared with 75% for older patients ( P = .04). The NB patients had 72% bNED control at 10 years compared with 58% for the bounce patients. The effect of a bounce remained statistically significant on multivariate analysis ( P < .0001). No statistically significant difference in DF, CSF, or OS was observed. CONCLUSIONS. Patients treated with external beam radiation therapy alone who experience a posttreatment PSA bounce have increased risk of BF. However, this did not translate into a difference in clinical failure with the available follow-up in the current study. Cancer 2006. © 2006 American Cancer Society. | en_US |
dc.format.extent | 140956 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone Presented at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Atlanta, GA, October 3–7, 2004. | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania ; Fax: (215) 214-1629 ; Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111-2497 | en_US |
dc.contributor.affiliationother | Department of Biomathematics, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Biomathematics, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Mallinckrodt Institute of Radiology, St. Louis, Missouri | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Division of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.identifier.pmid | 16944536 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/55827/1/22183_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.22183 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.